Bastian Dehmel

Corporate Officer/Principal at OCULIS HOLDING AG

54 year

Health Technology

Consumer Services

Bastian Dehmel active positions

Companies	Position	Start	End
OCULIS HOLDING AG	Corporate Officer/Principal	2021-12-31	-

Companies	Position	Start	End
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Chief Tech/Sci/R&D Officer	2017-09-30	2021-11-30
Amgen (Europe) GmbH	Corporate Officer/Principal	2013-11-30	2017-06-30

Freie Universität Berlin

Doctorate Degree

International

Operational

Corporate Officer/Principal	2
Chief Tech/Sci/R&D Officer	1
Doctorate Degree	1

Sectoral

Health Technology	3
Consumer Services	2

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	1
OCULIS HOLDING AG	Health Technology

Private companies	2
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology
Amgen (Europe) GmbH

Private companies

Health Technology

Amgen (Europe) GmbH